1 Correction to: BioDrugs https://doi.org/10.1007/s40259-022-00527-9
Fig. 1, the text in box “1st line metastatic” under “G/GOJ HER2 +ve”, which currently reads:
+ trastuzumab + nivolumab*.
Should read:
+ trastuzumab + pembrolizumab*
The original article has been updated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Booth, M.E., Smyth, E.C. Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. BioDrugs 36, 487 (2022). https://doi.org/10.1007/s40259-022-00535-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-022-00535-9